Tag: IP
Motilal Oswal Alternates invests USD 72 mn in Sensa Core Medical...
As per the company, this partnership underscores its commitment to support indigenous healthcare solutions that promise to transform patient outcomes
Morphle Labs raises $5Mn Series A from Inflexor Ventures to revolutionize...
Funding to accelerate market & team expansion, scale manufacturing, and deepen tech & IP leadership
Experts discuss IP & tech transfer best practices at World IP...
The event was supported by the National Biopharma Mission, BIRAC, and Institution’s Innovation Council (IIC)
ICRISAT shines spotlight on India’s intellectual property landscape
The institute aims to foster inclusive growth—advocating for stronger policies, efficient IP Management, robust licensing agreements, and effective technology transfer mechanisms.
Venture Center wins National Intellectual Property Award for nurturing IP
Venture Center is the winner in the category of “Best Incubator for Nurturing IP". The award was given on 15 Oct 2022 at an event in Delhi in the presence of the Minister of Commerce and Industry, Piyush Goyal
Data security a priority for pharma firms: Deloitte India–DSCI report
Ransomware attacks and IP and data theft were the top cybersecurity concerns for the sector. The pandemic and a rising number of targeted attacks have prompted certain pharma companies to double their cybersecurity investments
Sun Pharma Advanced Research signs licensing deal with Biomodifying LLC
SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
United States & India discuss IP-led solutions to the global pandemic
Although the global pandemic continues to affect millions, the 4th Annual IP Dialogue proved to be incredibly impactful, with intellectual property playing such a key role in efforts to study and combat the ongoing global pandemic.................................
United States & India discuss IP-led solutions to the global pandemic
3rd Annual IP Dialogue virtually convenes academic, industry, and public sector IP experts.................................
Price control in healthcare is a misguided policy!
While the NPPA identified the presence of information asymmetry in the market that leads to high prices of drugs and devices, it could have looked at affordability and access in a holistic manner, writes Dr Ashish Bharadwaj..............